FDA:
Silvergate Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BioMarin Pharmaceutical, Inc., Bayer HealthCare Pharmaceuticals, Inc., Horizon Pharma USA, Inc., Novartis, ARIAD Pharmaceuticals, Inc., Novatech SA, Mitsubishi Tanabe Pharma Corporation, NX Development Corporation, Janssen Biotech, Inc., Genentech, Inc., CSL Behring LLC, Arbor Pharmaceuticals, LLC, Emmaus Medical, Inc.
EMA:
Vall d’Hebron Institute of Research, Hôpital Foch, Sentinel Oncology Limited, PhaseRx Ireland, Mithra Pharmaceuticals S.A., Igenomix, S.L., Bluebird Bio France, IntraBio Ltd, GB Pharma Srl, NeoImmuneTech, Inc, Miragen Therapeutics Europe Ltd, Advicenne Pharma SA, Zealand Pharma A/S, Vale Pharmaceuticals Limited, ChemoCentryx Limited |